Research
Hormonal
Adaptive thermogenesis (AT) is primarily mediated by hormonal signals (leptin and insulin) that downregulate substrate cycling in skeletal muscle, reducing energy expenditure to preserve fat stores.
Understanding that hormones like leptin and insulin drive metabolic slowdown helps explain why weight loss stalls. This is not just 'willpower'; it is a hormonal defense of fat stores. Strategies that maintain muscle mass and avoid extreme deficits may mitigate the severity of this hormonal suppression.
GoodSupportsHIGH confidence
During periods of energy restriction, depleted TAG stores result in reduced leptin production, which directly downregulates substrate cycling in the skeletal muscle. Additionally, leptin indirectly downregulates skeletal muscle thermogenesis through suppression of sympathetic-thyroid axis...
Why this rating
Supported by specific mechanistic studies cited (e.g., Leibel et al., reference 131).
Source
Dynamic changes in energy expenditure in response to underfeeding: a review
Aoife M. Egan et al. · Proceedings of The Nutrition Society · 2021
DOI 10.1017/s0029665121003669
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Static energy balance models (e.g., the 3500 kcal rule) significantly overestimate weight loss because they ignore adaptive thermogenesis, which causes resting energy expenditure to drop beyond what is explained by the loss of metabolically active tissue.Good
- Metabolic adaptation (adaptive thermogenesis) is dynamic and largely reversible; it persists during negative energy balance but diminishes or disappears during weight stability or positive energy balance (refeeding).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →